Flecainide and Propafenone Safety in Patients With Non-Ischemic Cardiomyopathy

Key Points

• The study aims to evaluate the safety of flecainide and propafenone in patients with non-ischemic cardiomyopathy.
• Randomized trial design
• Inclusion of patients diagnosed with non-ischemic cardiomyopathy
• Comparison of safety profiles of flecainide and propafenone
• Flecainide demonstrated a 5% event rate for adverse effects compared to 7% for propafenone; p=0.02.
• Patients on flecainide experienced lower rates of arrhythmia-related events than those on propafenone; HR 0.75, 95% CI 0.55-0.98.
• Overall safety profiles differed, indicating flecainide might be preferred under specific circumstances.